MDT

88.44

+1.17%↑

120.85

+3.56%↑

VEEV

158.65

+0.37%↑

HQY

80.48

+0.9%↑

TLRY

6.89

+2.99%↑

MDT

88.44

+1.17%↑

120.85

+3.56%↑

VEEV

158.65

+0.37%↑

HQY

80.48

+0.9%↑

TLRY

6.89

+2.99%↑

MDT

88.44

+1.17%↑

120.85

+3.56%↑

VEEV

158.65

+0.37%↑

HQY

80.48

+0.9%↑

TLRY

6.89

+2.99%↑

MDT

88.44

+1.17%↑

120.85

+3.56%↑

VEEV

158.65

+0.37%↑

HQY

80.48

+0.9%↑

TLRY

6.89

+2.99%↑

MDT

88.44

+1.17%↑

120.85

+3.56%↑

VEEV

158.65

+0.37%↑

HQY

80.48

+0.9%↑

TLRY

6.89

+2.99%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Open

BrancheGesundheitswesen

0.41 5.13

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.39

Max

0.42

Schlüsselkennzahlen
By Trading Economics
Einkommen	983K -47M
Verkäufe	505K 14M
Gewinnspanne	-342.329
Angestellte	161
EBITDA	-346K -46M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+973.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-24M 81M
Vorheriger Eröffnungskurs	-4.72
Vorheriger Schlusskurs	0.41

Nachrichtenstimmung

By Acuity

61%

39%

307 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Apr. 2026, 23:25 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. Apr. 2026, 22:45 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. Apr. 2026, 18:03 UTC

Ergebnisse

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. Apr. 2026, 23:58 UTC

Ergebnisse

Review & Preview: Earnings Time -- Barrons.com

13. Apr. 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. Apr. 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. Apr. 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. Apr. 2026, 21:26 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. Apr. 2026, 21:23 UTC

Ergebnisse

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. Apr. 2026, 21:16 UTC

Ergebnisse

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

13. Apr. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. Apr. 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. Apr. 2026, 19:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. Apr. 2026, 19:27 UTC

Market Talk

Wichtige Nachrichtenereignisse

Correction to Precious Metals Market Talk on April 9

13. Apr. 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. Apr. 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

973.17% Vorteil

12-Monats-Prognose

Durchschnitt 4.4 USD 973.17%

Hoch 15 USD

Tief 0.3 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

307 / 348 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.